Leyden Labs

Leyden Labs is a biotech company that helps people live freely by developing products that protect from known and new respiratory viruses.

Leyden's platform targets commonalities of viral families to protect humanity from known and future viruses.

Leyden Labs was founded in 2020 by Jaap Goudsmit, Koenraad Wiedhaup, and Ronald Brus. The company is headquartered in Amsterdam, North Holland, Netherlands.

 

Leyden's portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families.

 

Leyden Labs’ platform is built on two innovative concepts: broad protection against known viruses, new variants and newly emerging viruses, and protection at the gate, in the mucosa (e.g. in the nose and throat).

 

Leyden Labs has a pipeline of mucosal protection products, including PanFlu which uses CR9114, the only human monoclonal influenza antibody that protects against influenza A and B, in-licensed from Janssen Pharmaceuticals.

 

Leyden is backed by Casdin Capital, GV, F-Prime Capital, SoftBank Vision Fund 2, Invus, Byers Capital/Brook Byers, Bluebird Ventures, and others. The company raised $140M in Series B round on Jan 25, 2022. This brings Leyden's total funding to $188M to date.

 

 

 

  • Year founded: 2020
  • Funding Info: $188M over 2 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Amsterdam
  • State: North Holland
  • Country: Netherlands
Related businesses